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1.1. Deﬁnition
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OR, odds ratio; HR, hazard ratio.increase of the portal pressure gradient (the pressure dif-
ference between the portal vein and the inferior vena
cava) and by the formation of portal–systemic collater-
als that shunt part of the portal blood ﬂow to the sys-
temic circulation bypassing the liver [1]. Normal values
of the portal pressure gradient are of 1–5 mm Hg.
Clinically signiﬁcant portal hypertension (CSPH) is
diagnosed when clinical manifestations of the disease
appear or when portal pressure gradient – in case of cir-
rhosis determined by its equivalent, the hepatic venous
pressure gradient (HVPG) [2] – exceeds a threshold
value of 10 mm Hg. Values of portal pressure gradient
between 5 and 9 mm Hg correspond to pre-clinical por-
tal hypertension [3–6].
1.2. Aetiology and classiﬁcation (Table 1)
Portal hypertension can arise from any condition
interfering with blood ﬂow at any level within the portal
system. According to the anatomic location of the
obstacle to blood ﬂow the causes of portal hypertension
can be classiﬁed as prehepatic (involving the splenic,Published by Elsevier B.V. All rights reserved.
Table 1
Classiﬁcation of portal hypertension according to the anatomic site of
increased resistance to portal blood ﬂow
Prehepatic
Splenic vein thrombosis
Portal vein thrombosis
Congenital stenosis of the portal vein
Extrinsic compression of the portal vein
Arteriovenous ﬁstulae
Intrahepatic
Cirrhosis (viral, alcoholic, biliary, metabolic)
Granulomatous diseases (schistosomiasis, sarcoidosis,
tuberculosis, PBC)
Partial nodular transformation*
Nodular regenerative hyperplasia*
Congenital hepatic ﬁbrosis
Peliosis hepatis
Polycystic disease*
Idiopathic portal hypertension*
Hypervitaminosis A
Arsenic, copper sulfate, vinyl chloride monomer poisoning
Amyloidosis
Mastocytosis
Rendu-Osler-Weber sı´ndrome
Liver inﬁltration in hematologic diseases
Acute fatty liver of pregnancy
Severe acute viral and alcoholic hepatitis
Chronic active hepatitis
Hepatocellular carcinoma
Cyanamide toxicity
Veno-occlusive disease
Posthepatic
Hepatic vein thrombosis (Budd-Chiari syndrome)
Congenital malformations and thrombosis of the inferior vena
cava
Constrictive pericarditis
Tricuspid valve diseases
* Exhibit a ‘‘pre-sinusoidal” pattern.
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and posthepatic (diseases blocking the hepatic venous
outﬂow).
Cirrhosis of the liver determines about 90% of cases
of portal hypertension in Western countries, while
Schistosomiasis is the ﬁrst cause in other countries.
Other causes of portal hypertension account for
less than 10% of cases worldwide, which explains why
these are frequently referred to as non-cirrhotic portal
hypertension.
The more frequent cause of prehepatic portal hyper-
tension is portal vein thrombosis (PVT). In children this
is often secondary to omphalitis, while in adults thromb-
ophilic syndromes, either congenital (such as protein C
and S deﬁciency) or acquired (such as latent myelopro-
liferative disease) in addition to local factors (such as
sepsis, abdominal trauma or surgery) can explain the
onset of thrombosis in up to 70% of cases [7]. In about
30% these factors are not identiﬁed (‘‘idiopathic” PVT)
[7]. Acute portal vein thrombosis is uncommon, usually
manifested by abdominal pain and fever; in few cases
with extended thrombosis, diarrhoea and ileus mayappear as a consequence of intestinal infarction. The
diagnosis is usually made by imaging techniques.
Chronic PVT is characterized by the formation of collat-
eral vessels that ‘‘bridge” the obstruction, causing the
appearance of the so-called portal ‘‘cavernoma”.
Patients with chronic PVT develop the same hemody-
namic abnormalities as in other causes of portal hyper-
tension, and are frequently diagnosed after a ﬁrst
episode of variceal bleeding. Gastric varices are a fre-
quent ﬁnding in PVT: Treatment options include antico-
agulation in the acute phase (which should be perpetual
in patients with thrombophilic disorders), and medical
and endoscopic therapy for portal hypertension compli-
cations in the chronic phase.
The more frequent cause of posthepatic portal hyper-
tension is the Budd-Chiari syndrome (hepatic vein
thrombosis). Obstruction can occur at the main hepatic
veins or in suprahepatic inferior vena cava. Similarly to
PVT, one or several underlying prothrombotic disorders
are usually present, the most common of which is an
overt or occult primary myeloproliferative disorder.
Major complications are ascites and gastrointestinal
bleeding associated with a variable degree of liver fail-
ure. The disease can present as an acute, subacute or
chronic disease. Diagnosis is usually made by imaging
techniques [8,9]. Treatment includes anticoagulation to
prevent recurrence or extension of thrombosis, treat-
ment of ascites and gastrointestinal bleeding, and proce-
dures aiming at re-establishing hepatic blood outﬂow.
Transjugular intrahepatic porto-systemic shunt (TIPS)
has substituted derivative surgery in patients who do
not improve with medical treatment. Transplantation
is proposed for patients with severe liver failure [10,11].
Intrahepatic causes of portal hypertension have been
classiﬁed according to the results of hepatic vein cathe-
terisation. This classiﬁcation includes:
(a) pre-sinusoidal PH: normal wedged and free hepatic
venous pressure (WHVP and FHVP);
(b) sinusoidal PH: increased WHVP and normal
FHVP;
(c) post-sinusoidal PH: increased WHVP and FHVP.
Some disorders may act at several sites; for example,
in Schistosomiasis portal hypertension is the conse-
quence of the formation of granulomas due to the depo-
sition of parasite eggs in portal venules. The
inﬂammatory response induces ﬁbrosis and obliteration
of portal venules (pre-sinusoidal PH), which later
extends to sinusoids (sinusoidal PH). At this time the
hemodynamic and clinical pattern resemble those of
liver cirrhosis.
Any cause of chronic liver disease, except chronic
cholestatic syndromes cause sinusoidal PH. Since cirrho-
sis is the leading cause of PH, the next sections of this
article will focus on cirrhotic portal hypertension.
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The relevance of the portal hypertensive syndrome is
due to the frequency and severity of its complications,
which represent the ﬁrst cause of hospital admission,
death and liver transplantation in patients with cirrhosis.
Cirrhotic portal hypertension is a vascular disease which
involves several systems and organs [12]. The main man-
ifestations are brieﬂy summarized in this section.
Splanchnic vascular bed. Cirrhosis causes marked
alteration in this territory, featuring splanchnic vasodi-
lation, decreased responsiveness to vasoconstrictors
and formation of new blood vessels (angiogenesis)
which contribute both to increase of splanchnic blood
ﬂow (arteriolar-capillary network), and portal–systemic
collaterals [13] such as gastro-oesophageal varices, portal
hypertensive gastropathy and colopathy, which are
responsible for variceal bleeding episodes. Portal–sys-
temic shunting is also involved in portal–systemic
encephalopathy and other complications.
Systemic circulation. Portal hypertension is typically
associated with a hyperkinetic syndrome, characterized
by hypervolemia, increased cardiac index, hypotension
and decreased systemic vascular resistance [14]. The
hyperkinetic syndrome leads to a situation of hypoten-
sion and ‘‘eﬀective” hypovolemia, volume receptors
being stimulated despite the increased circulating blood
volume. This leads to a marked activation of neuro-
humoral vasoactive factors in an attempt to maintain
the arterial blood pressure within normal values, which
plays a leading role in the pathophysiology of ascites
and renal dysfunction in chronic liver disease [15]. Once
ascites has formed, it can get infected by enteric bacteria
which translocate from the bowel, causing spontaneous
bacterial peritonitis.
Kidney. Renal abnormalities in cirrhosis are mostly
functional, and characterized by marked renal vasocon-
striction, responsible for the development of hepato-
renal syndrome. As mentioned, renal vasoconstriction
develops as a consequence of the splanchnic vasodila-
tion and systemic hyperkinetic syndrome [15]. These
concepts had provided the rationale for treating the hep-
ato-renal syndrome with albumin infusion and vasocon-
strictors (terlipressin, norepinephrine or midodrine) [16].
Lung. Vasodilatation in the lung leads to ventilation
perfusion mismatch and even to A–V shunts in the pul-
monary circulation; these determine the hepatopulmonary
syndrome, characterized by marked hypoxemia [17,18].
In some cases, this may evolve into the opposite situation,
porto-pulmonary hypertension, characterized by a
marked increase of pulmonary vascular resistance [19].
The latter is thought to develop through endothelial
dysfunction and vascular remodelling of the pulmonary
circulation [20].
Heart. Portal hypertensive patients typically show a
chronically increased cardiac output. Some patientsexhibit electrophysiological changes such as QT prolon-
gation and impaired ventricular contractility in response
to both physiological and pharmacological stimuli. This
constellation of cardiac abnormalities is termed
‘‘cirrhotic cardiomyopathy” [21]. In terminal stages of
cirrhosis, especially in patients with sepsis and/or hep-
ato-renal syndrome the cardiac output may decrease,
which may be of clinical relevance contributing to fur-
ther aggravate renal failure [22]. To what extent this is
caused by the cirrhotic cardiomyopathy or by the release
of cardiodepressing cytokines prompted by sepsis
remains uncertain.
Blood abnormalities. Thrombocytopenia, leucopoenia
and anaemia are frequent ﬁndings in portal hypertensive
patients. Increased portal pressure plays a central role
leading to splenomegaly, with consequent pooling and
sequestration (the so-called hypersplenism) of corpuscu-
lar elements of the blood, predominantly thrombocytes.
Moreover, liver failure reduces the hepatic synthesis of
lineage-speciﬁc cytokine thrombopoietin (TPO), leading
to reduced thrombopoiesis in the bone marrow and con-
sequently to thrombocytopenia [23].
Brain. Changes in cerebral blood ﬂow and vascular
reactivity associated with portal hypertension are
thought to facilitate some of the brain abnormalities
of hepatic encephalopathy.
Skin. Advanced cirrhosis is characterized by warm
skin, bounding pulses and palmar erythema, which all
reﬂect the participation of the peripheral circulation in
the hyperkinetic syndrome. In addition, dermal angio-
genesis gives raise to the spider angioma characteristic
of advanced liver disease. Hepatopulmonary syndrome
may cause ﬁnger clubbing.2. Natural history and prognosis of gastro-oesophageal
varices
Variceal bleeding is the last step in a chain of events
initiated by an increase in portal pressure, followed by
the development and progressive dilation of varices until
these ﬁnally rupture and bleed. It has been estimated
that varices are present in about 30–40% of compen-
sated patients at the time of diagnosis, and in 60% of
decompensated patients [4,24,25]. In cirrhotic patients
without varices at ﬁrst endoscopy the annual incidence
of new varices is 5–10% in published series [26–28].
Varices may appear when HVPG increases above
10 mm Hg [4,29]. A HVPG over 10 mm Hg is a strong
predictor for the development of varices [4].
Once developed, varices usually increase in size from
small to large before they eventually rupture and bleed.
The reported rate of progression is heterogeneous
(5–30% per year) [27,28,30,31]. The factor that has been
most consistently associated with variceal progression
is liver failure, as assessed by Child-Pugh class
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of cirrhosis and presence of red wale markings at the
varices [28,31]. Changes in HVPG (either ‘‘spontane-
ous” or caused by drug therapy or TIPS) are usually
accompanied by parallel variations in the size of the
oesophageal varices, which are signiﬁcantly reduced
when HVPG decreases below 12 mm Hg [6,33].
In patients with cirrhosis the overall incidence of var-
iceal bleeding is about 4% per year. This risk increases to
15% per year in patients with medium–large varices [25].
The most important predictive factors related to the risk
of bleeding are variceal size, Child-Pugh class and pres-
ence of red signs [34]. In addition, many studies have
shown that variceal bleeding only occurs if the HVPG
reaches a threshold value of 12 mm Hg [5,6,29]. Con-
versely, if the HVPG is substantially reduced (below
12 mm Hg or by more than 20% of baseline levels) there
is a marked reduction in the risk of bleeding [6,35], thus
demonstrating that the portal hypertension syndrome
might be reversed if portal pressure is suﬃciently
reduced.3. Treatment strategies and scenarios
3.1. Aims and rationale
Once portal pressure increases above a critical thresh-
old value complications of portal hypertension can
appear. Varices do not develop until the hepatic venous
pressure gradient (HVPG), increases to 10–12 mm Hg,
and it should be of at least 12 mm Hg for the appear-
ance of other complications, such as variceal bleeding
or ascites [5,29,36]. Longitudinal studies have demon-
strated that if HVPG decreases below 12 mm Hg by
means of pharmacological treatment [37], alcohol with-
drawal or spontaneously due to an improvement in liver
disease [33], variceal bleeding is totally prevented and
varices may decrease in size. Besides, even if this target
is not achieved, a 20% decrease in portal pressure from
baseline levels (or greater) also oﬀers a marked protec-
tion from variceal bleeding [37]. Furthermore, achieve-
ment of these targets may be associated with a lower
risk of developing ascites, spontaneous bacterial perito-
nitis, hepatorenal syndrome and death [38], thus demon-
strating the reversibility of the portal hypertensive
syndrome. These ﬁndings provide the rationale for treat-
ments aimed to reduce portal pressure in patients with
portal hypertension.
3.2. Therapeutic reduction of portal pressure
In cirrhosis, increase in vascular resistance to portal
blood ﬂow at the hepatic microcirculation is the initial
factor leading to portal hypertension. Contrary to what
was traditionally thought, this increased hepatic vascu-lar resistance is not only a mechanical consequence of
the hepatic architectural distortion caused by ﬁbrosis,
nodule formation, sinusoidal remodelling and vascular
occlusion characteristic of cirrhotic, but there is also a
dynamic component, due to the active contraction of
portal/septal myoﬁbroblasts, activated hepatic stellate
cells and vascular smooth muscle cells in portal venules
[39–41] which is due to an imbalance between increased
vasoconstrictor stimuli in the presence of impaired vaso-
relaxating mechanisms [42]. Thus, in cirrhotic liver there
is an increase in the activity of several endogenous vaso-
constrictors such as endothelin, leukotrienes or throm-
boxane A2 among others [43] and a reduced nitric
oxide bioavailability [39,44–46] (Fig. 1). It is estimated
that about one-third of the increased resistance to portal
blood ﬂow through the cirrhotic liver is due to this
dynamic component.
Reducing intrahepatic resistance either by improving
the architectural abnormalities or by reducing the
increased hepatic vascular tone of the cirrhotic liver will
decrease portal pressure. Such an approach would have
the additional advantage of improving liver perfusion
and thereby, liver function.
Improvement in liver architecture may be achieved
using drugs or cell therapy to prevent/reverse sinusoidal
remodelling and ﬁbrogenesis [15] or by speciﬁc treat-
ments for the underlying liver disease (interferon and
antivirals for chronic hepatitis C and B, iron depletion
for haemochromatosis, copper chelation for Wilson’s
disease, and alcohol abstinence for alcoholism). For each
of these treatments there is evidence showing reduction in
portal pressure with successful therapy [16,17].
Restoring the equilibrium between vasodilator and
vasoconstrictor forces within the liver circulation would
reduce the hepatic vascular tone and resistance of the
cirrhotic livers. This could be achieved by improving
intrahepatic NO availability by means of increasing its
production either by NOS [47] or aAKT [48] gene-trans-
fer; by the development of liver-speciﬁc NO-donors
[49,50]; by posttranslational upregulation of eNOS using
statins [51,52] or tetrahydrobiopterin supplementation
[46], and by preventing NO scavenging using anti-oxi-
dant [53] or SOD gene-transfer [54]. Other potential
approaches are the inhibition of the vasoconstrictor sys-
tem COX-1/TXA2 pathway [55–57] or increasing H2S
[58].
The increased resistance through the cirrhotic liver
can also be targeted by ‘‘mechanical” means, bypassing
the liver. This can be achieved by portal–systemic shunt
surgery and by transjugular intrahepatic portal–systemic
shunts (TIPS). These procedures are highly eﬀective in
decreasing portal pressure, but have the detrimental
eﬀect that, by further decreasing portal blood ﬂow
through the liver and by increasing portal–systemic
shunting may enhance liver failure and facilitate hepatic
encephalopathy.
Fig. 1. Pathophysiology of portal hypertension: the diﬀerent contributors to the increased portal pressure represent speciﬁc targets for therapy. Current
treatments are all based on correcting the increased portal inﬂow. New treatments acting on the remaining determinants of portal hypertension are being
actively investigated.
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an increased blood ﬂow through the portal venous system
due to splanchnic arteriolar vasodilatation. This is caused
by an excessive release of endogenous vasodilators (endo-
thelial and neuro-humoral) [59–63]. Splanchnic hypera-
emia contributes to aggravating the increase in portal
pressure and explains why portal hypertension persists
despite the establishment of an extensive network of por-
tal–systemic collaterals that may divert over 80% of the
portal blood ﬂow. The increased portal venous inﬂow
can be corrected pharmacologically by means of splanch-
nic vasoconstrictors such as vasopressin and its deriva-
tives, somatostatin and its analogues and non-selective
beta-adrenergic blockers, which are the drugs that have
more widely been used in the treatment of portal hyper-
tension. Splanchnic vasodilatation is in part due to an
increased release of NO, which is amendable to pharma-
cological manipulation. However, this faces the diﬃculty
of inhibiting NO synthesis only in the splanchnic circula-
tion, which is not feasible at present.
Splanchnic vasodilatation is accompanied by
increased cardiac index and hypervolemia, representing
the hyperkinetic circulatory syndrome associated with
portal hypertension [15,64]. An expanded blood volume
is necessary to maintain the hyperdynamic circulation,
which provides a rationale for the use of low-sodium
diet and spironolactone to attenuate the hyperkinetic
syndrome and the portal pressure elevation in patients
with cirrhosis [65].
Combined pharmacological therapy attempts to
enhance the reduction of portal pressure by associatingvasoconstrictive drugs, which act by decreasing portal
blood inﬂow, and vasodilators, which reduce the intra-
hepatic vascular resistance [66]. Table 2 summarizes
the diﬀerent drugs and its dose that have been shown
to reduce portal pressure in cirrhosis.
Recent studies have demonstrated that VEGF/
PDGF mediated angiogenesis plays a relevant role in
sinusoidal remodelling and liver ﬁbrogenesis, in the for-
mation of portal–systemic collaterals and in the develop-
ment of a hyperkinetic splanchnic circulation [67,68].
Studies blocking VEGF by a variety of approaches have
shown that this is associated with a decreased formation
of portal–systemic collaterals and to reduced porto-col-
lateral blood ﬂow. Furthermore, the combined blockade
of VEGF and PDGF results in a marked fall in portal
pressure. Even in conditions not decreasing portal pres-
sure VEGF blockade may prevent collateralization by
over 50% [13,67]. This is a new concept, challenging
the traditional hypothesis that formation of collaterals
(including varices) was only the result of the dilation
by the increased portal pressure of pre-existing but func-
tionally closed vascular channels at sites of communica-
tion between the portal and systemic circulation, and
emphasizes that antagonizing angiogenesis may repre-
sent a new therapeutic target for portal hypertension
[42,69].
3.3. Local treatments
In addition to pathophysiological oriented treat-
ments, there are several other approaches that have been
Table 2
Drugs used to reduce portal pressure in cirrhosis and their dosage
Drug Administration Dose Period of administration
Vasopressin (VP) + nitroglycerin
(NG)
VP: i.v. infusion NG: percutaneous VP: 0.4 uu/min NG: 20 mg 2–5 days (acute bleeding)
Terlipressin i.v. boluses 2 mg/4 h for 24–48 h then 1 mg/4 h 2–5 days (acute bleeding)
Somatostatin i.v. bolus then i.v. infusion 250 mcg followed by 250–500 mcg/h 2–5 days (acute bleeding)
Octreotide i.v. bolus then i.v. infusion 50 mcg followed by 50 mcg/h 2–5 days (acute bleeding)
Vapreotide i.v. bolus then i.v. infusion 50 mcg followed by 50 mcg/h 2–5 days (acute bleeding)
Propranolol (non-selective BB) Oral 20 mg bid; increase the dose up
to the maximum tolerated
(maximum 320 mg/day)
Chronic (primary and secondary
prophylaxis)
Nadolol (non-selective BB) Oral 40 mg bid; increase the dose up
to the maximum tolerated
(maximum 160 mg/day)
Chronic (primary and secondary
prophylaxis)
Carvedilol (non-selective BB
with alfa-blocker activity)
Oral 6.25 mg bid; increase the dose up
to the maximum tolerated
(maximum 50 mg/day)
Chronic (primary and secondary
prophylaxis)
Isosorbide mononitrate Oral 10–20 mg bid; increase up to
20–40 bid if tolerated
Chronic, only in association
with BB (primary and secondary
prophylaxis)
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to portal hypertension.
Endoscopic treatments are directed at ‘eradicating’ the
varices either by injecting a variety of irritating sub-
stances into or around the varices to promote thrombo-
sis and ﬁbrosis, or by ligating the varices using elastic
bands. These treatments do not decrease portal pressure
and therefore its eﬀects are of limited duration. Local
treatments have no eﬀect on other complications of por-
tal hypertension. Moreover, it is possible that the eﬃ-
cacy of endoscopic therapy can be enhanced if
combined with an agent that eﬀectively lowers portal
pressure [70]. However, if the decrease in portal pressure
gradient is greater than 20% of baseline or to values
below 12 mm Hg there is probably no need for associat-
ing any invasive endoscopic procedures.
Balloon tamponademay temporarily control bleeding in
60–90%ofpatients.However, ondeﬂationof theballoons,
bleeding recurs in about 50% of cases [71]. Balloon tam-
ponade is used only for 12–24 h in emergency situations
as a bridge todeﬁnitive therapy if drugs and endoscopy fail
to control variceal bleeding. Severe complications occur in
10–15% of patients and consist mainly of aspiration
pneumonia and, rarely, oesophageal rupture. Complica-
tion-related mortality ranges between 2% and 5%. Only
well-trained personnel should attempt tamponade [71].
Expandable oesophageal stents. It has been recently
suggested in a small series of cirrhotic patients with
uncontrolled bleeding from oesophageal varices that
the implantation of covered expandable oesophageal
stents may be a safe and eﬀective alternative to balloon
tamponade [70,72]. These promising results will have to
be conﬁrmed in comparative studies including larger
number of patients.
Hemostatic agents, such as recombinant activated
factor VII, are being explored as adjuvants to conven-tional therapy to arrest variceal bleeding in patients with
poor liver function [73,74].
3.4. Clinical scenarios for treatment
The treatment of portal hypertension takes place in
diﬀerent scenarios, which go from the asymptomatic
patient who has never bled from varices, to the treat-
ment of the acute variceal bleeding episode and the pre-
vention of recurrent bleeding. The main diﬀerence
between these scenarios is that natural history and prog-
nosis is very diﬀerent from one to another. This knowl-
edge of the natural history of each of these situations
should guide the selection of therapies, since the eﬃcacy
of the available treatments is inversely proportional to
their invasiveness and adverse eﬀects.4. The compensated patient: prevention of ﬁrst bleeding
4.1. Who should be treated? Diagnosis and screening
policy
4.1.1. Screening for varices: when and how
The main aim for screening patients for oesophageal
varices is to detect those requiring prophylactic treat-
ment. In addition, the appearance of varices in compen-
sated cirrhotic patients identiﬁes a change from a clinical
stage with a very low risk of death at 1 year (stage 1; 1%
risk) to an intermediate risk stage (stage 2; 3.4% risk)
[75]. Therefore, the current consensus is that every cir-
rhotic patient should be endoscopically screened for var-
ices at time of diagnosis [27]. In patients without varices
on initial endoscopy, a second (follow-up) evaluation
should be performed after 2–3 years [70]. High-risk var-
ices call by prophylactic treatment. They include ‘‘large”
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red colour signs or in a Child-Pugh class C patient. Since
endoscopy is somehow invasive, and not all patients
agree to adhere to repeated endoscopic evaluations,
non-invasive substitutes for endoscopy have been pro-
posed. Unfortunately, none of the available non-inva-
sive tests has proved to be accurate enough as to
avoid endoscopy in patients with negative indicators
[76,77]. However, some clinical, laboratory and imaging
variables may help in selecting the group of patients at
high risk for varices [78,79].
Non-invasive tests
Physical examination. Physical stigmata of cirrhosis
are a palpable ﬁrm left hepatic lobe [80], gynaecomastia,
testicular atrophy, parotidomegaly, jaundice, vascular
spiders, leuconykia, palmar erythema, signs of hepatic
encephalopathy, presence of abdominal wall collateral
circulation, ascites, leg oedema and splenomegaly
(which may be considered the single most important
diagnostic sign of portal hypertension). In addition,
hypotension, bounding pulses, and tachycardia, reﬂect
the hyperdynamic circulation. A systematic review of
the diagnostic accuracy of physical examination for
the detection of cirrhosis found that all these physical
ﬁndings are highly speciﬁc [81]. However these ﬁndings
are more common in decompensated disease. The sensi-
tivity of physical signs is much lower in compensated cir-
rhosis, where non-invasive diagnosis would be more
valuable.
Clinical/biological markers of CSPH. Child-Pugh
score has been shown to correlate with portal pressure
[82–84] and with the prevalence and grade of oesopha-
geal varices. In patients with cirrhosis, platelet count
was independently correlated with the prevalence and
grade of oesophageal varices in several studies, although
its predictive value is far from ideal [85–87]. Giannini
et al. showed that platelet count/spleen diameter ratio
above 909 has a 100% negative predictive value for the
presence of oesophageal varices [79]. This index may
help in reducing the number of endoscopies for the
screening of oesophageal varices.
Imaging techniques
Ultrasound and duplex-Doppler. Splenomegaly (spleen
length >13 cm) is the ultrasonographic ﬁnding more fre-
quently associated with portal hypertension and with
oesophageal varices. Other US-Doppler measurements,
related with portal hypertension include: dilated portal
vein (diameter above 13 mm) [88]; lack or reduced respi-
ratory variations of splenic and superior mesenteric vein
diameter [89]; reversal of portal blood ﬂow; reduced por-
tal vein velocity (maximal and mean velocimetry of por-
tal vein ﬂow, respectively, <20 cm/s and <10–12 cm/s)
[90]; increased congestion index of portal vein [91]; pres-
ence of portal–systemic collateral circulation [92];
altered hepatic venous Doppler pattern [93], increasedintraparenchymal hepatic and splenic artery impedance
[94–96]; increased intraparenchymal renal artery imped-
ance [97] and reduced mesenteric artery impedance [98].
Besides, US-Doppler is very useful to assess portal vein
patency.
Other imaging techniques. Computed tomographic
scan (CT) and magnetic resonance (MRI) allow an accu-
rate visualization of portal venous system. Recently,
dynamic contrast-enhanced single-section CT scans
and MRI (compartmental analysis of intensity versus
time curves for magnetic resonance images of the liver
after injection of a gadolinium chelate) and phase con-
trast MR angiography have been described to permit
an observer independent quantitative measurement of
portal [99] and azygos [100] blood ﬂow. Portal fraction
of liver perfusion and mean transit time at MRI have
been suggested to correlate with HVPG [101]. However,
whether any of these rather expensive techniques add
signiﬁcantly to clinical, biochemical or US parameters
is not known.
Elastography. Liver stiﬀness measurement by tran-
sient elastography (FibroScan) is a new non-invasive
method based on the measurement by means of an ultr-
asonographic transducer of the velocity of propagation
of a low frequency vibration wave. The velocity of prop-
agation of the wave is directly related to the tissue stiﬀ-
ness, which correlates with ﬁbrosis in liver disease
[102,103]. Liver stiﬀness has been shown to predict cir-
rhosis in diﬀerent studies, with good accuracy but with
diﬀerent cut-oﬀs depending on the underlying aetiology.
Liver stiﬀness measurements have been recently evalu-
ated for the prediction of CSPH, since up to 40% of
compensated cirrhotic patients do not have CSPH [4]
and could safely avoid endoscopic screening. Liver stiﬀ-
ness showed an excellent correlation with ﬁbrosis and
with HVPG in patients with recurrent HCV infection
after OLT [104]. In this study, a liver stiﬀness value
P8.74 kPa had a sensitivity and speciﬁcity of 90% and
81% for the diagnosis of portal hypertension
(HVPGP 6 mm Hg). In cirrhosis, liver stiﬀness has
been shown to correlate with the presence of large
oesophageal varices [105]. A liver stiﬀness >19 kPa pre-
dicted the presence of large oesophageal varices. Yet,
other values have been proposed by other studies
[106]. Two recent studies showed that the cut-oﬀ values
of 23 and 13.6 kPa have a good capacity to predict the
presence of CSPH in patients with chronic liver disease
[107,108], but above the threshold value of 13.6 kPa
the correlation between liver stiﬀness and HVPG was
poor, suggesting that once portal–systemic collaterals
develop, structural abnormalities within the liver (e.g.
ﬁbrosis) are no longer the main determinant of portal
hypertension.
Thus, it appears that the ﬁnding of a high value of
liver stiﬀness (the cut-oﬀ still not well deﬁned) has
potential to predict cirrhosis and probably the presence
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assess portal pressure in advanced stages. Other limita-
tions of liver stiﬀness measurements are that it cannot
be used in obese or ascitic patients, and that liver inﬂam-
mation increases the values independently of the degree
of ﬁbrosis.
MR elastography is a novel method proposed to eval-
uate liver stiﬀness. The measurement is obtained by syn-
chronizing motion-sensitive imaging sequences with the
application of acoustic waves in tissue media [109]. Pre-
liminary results support its practicability in predicting
the stage of ﬁbrosis in patients with chronic liver disease
[110]. MR elastography has technical advantages over
Fibroscan (no need for an acoustical window, a freely-
oriented ﬁeld of view, and the insensitivity to obesity),
but it is much more expensive and time consuming.
Procedures
Endoscopy. Upper gastrointestinal endoscopy is man-
datory in patients with cirrhosis in whom portal hyper-
tension is suspected. It allows the assessment of the
presence and size of oesophageal and gastric varices,
the presence of red signs in the variceal wall and the
presence and severity of portal hypertensive gastropa-
thy. The use of conscious sedation markedly increases
the patients’ compliance to the procedure.
Endoscopic videocapsule. This has been recently
introduced as it may improve patients’ tolerance. Once
swallowed, the videocapsule records images at pre-deter-
mined intervals. In the two published studies, capsule
endoscopy allowed a correct identiﬁcation of varices in
80% of cases [111,112]; in one of these studies capsule
endoscopy allowed the identiﬁcation of red wale marks
[111]. However it may not be as good in assessing vari-
ceal size and it may have poor accuracy in identifying
the presence of hypertensive gastropathy and that of
gastric varices [113]. Further data is required before it
could be recommended for the routine screening of var-
ices in patients with cirrhosis.
HVPG measurement. HVPG measurement is the gold
standard technique to evaluate the presence and severity
of portal hypertension. Measurement of HVPG at hepa-
tic vein catheterisation is an objective and quantitative
equivalent of portal pressure in cirrhosis [2]. HVPG has
proved to add prognostic information in many settings,
including compensated cirrhosis, acute variceal bleeding
[114], and patients awaiting liver transplantation [115].
Patients with CSPH are at high risk of varices and should
undergo endoscopic screening. Furthermore, changes in
HVPG during therapy provide robust prognostic infor-
mation (see below).4.1.2. Who should be treated?
As previously discussed, the current consensus is that
every cirrhotic patient should be endoscopically
screened for varices at time of diagnosis [27]. In patientswithout varices on initial endoscopy, a second (follow-
up) evaluation should be performed after 2–3 years
[70]. Since endoscopy is unpleasant for the patient,
and screening in all cirrhotic patients is a substantial
burden empirical beta-blocker therapy for all patients
has been proposed. Two studies suggest that this strat-
egy is cost eﬀective [116,117], but a third suggested that
this strategy is cost eﬀective only in patients with decom-
pensated cirrhosis [118].
Patients without varices.Based on results in experimen-
talmodels of portal hypertension [119] non-selective beta-
adrenergic blockers were proposed for the prevention of
the development of varices. To test this hypothesis, in a
large multicenter study 213 patients with cirrhosis and
portal hypertension (HVPG > 5 mm Hg) but without
varices were randomised to receive timolol or placebo in
double-blind conditions for a median of 55 months [4].
The primary endpoint was development of oesophageal
varices or variceal haemorrhage. The rate of development
of the primary endpoint did not diﬀer between the two
treatment groups and adverse events were more frequent
in the timolol group. Therefore, beta-adrenergic blockers
cannot be recommended for the prevention of the devel-
opment of oesophageal varices. Recent studies have
shown that blockade of the vascular endothelial growth
factor (VEGF) signalling cascade is highly eﬀective reduc-
ing the formation of collaterals in experimental models
[13,67], but no study has explored this clinically. As
already discussed, a diﬀerent approach is to prevent the
progression of cirrhosis (i.e. abstinence in alcoholics,
antivirals in viral cirrhosis, lifestyle change inNASH, cor-
ticosteroids in autoimmune hepatitis, phlebotomies in
haemochromatosis, copper chelators inWilson’s disease).
Patients with high-risk varices. In the past only
patients with medium to large varices were considered
for prophylactic treatment of variceal bleeding. This
was due to the fact that most studies with beta-adrener-
gic blockers were performed in patients with medium to
large varices, while the beneﬁcial eﬀects of beta-blockers
are less clear in patients with small varices [120]. How-
ever, the classiﬁcation of varices according to their size
is subjective and at the recent Baveno IV consensus con-
ference it was not possible to agree on a clear deﬁnition
of small and big varices [70]. On the other hand, it is well
established that ‘‘small” (F1) varices with red signs or in
Child-Pugh C class patients have a bleeding risk similar
to that of big varices [34]. Also, beta-adrenergic blockers
may reduce the rate of progression from small to large
varices, and decrease the incidence of variceal bleeding
in patients with small varices [27]. Thus, current guide-
lines recommend initiating beta-blockers in patients
with high-risk varices. These include patients with mod-
erate to large varices, and patients with small varices
with red signs or Child-Pugh C [70]. No follow-up
endoscopy is needed once the patient is under
beta-blockers. If beta-blockers are not initiated in
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be performed every 1–2 years, or if the patient
decompensates.
4.2. Treatments for the prevention of ﬁrst bleeding: beta-
adrenergic blockers vs endoscopic band ligation (Text Box 1)
Non-selective beta-adrenergic blockers (propranolol
or nadolol) have been shown to reduce the risk of ﬁrst
variceal bleeding (from 24% to 15% after a median fol-
low-up 2 years) and mortality (from 27% to 23%)
[120]. It is important to note that beta-blockers are
among the safest and cheapest drugs in Europe. How-
ever, circa 25% of cirrhotic patients with high-risk
oesophageal varices may have either contraindications
for the administration of non-selective beta-blockers or
cannot tolerate these drugs. Additionally, the degree of
protection (about 40% relative risk reduction on an
intent-to-treat basis) is not ideal.
Text Box 1
Prophylaxis of ﬁrst variceal bleeding: recommendations Patients without varices should be screened endoscop-
ically for the appearance of varices every 2–3 years. In
patients with small varices it is indicated to repeat
endoscopy every 1–2 years. The interval should be
shortened in patients with HVPGP 10 mm Hg.
 Patients with moderate/large varices should be
treated with a non-selective beta-blocker if there are
no contraindications.
 Patients with small varices with red signs or with
advanced liver failure (Child-Pugh C) are at similar
risk of bleeding as those with moderate/large vari-
ces and should be considered for preventive therapy
 Patients with moderate/large varices with
contraindications to or who cannot tolerate beta-
blockers should be oﬀered endoscopic band ligation.
Band ligationmight be used as ﬁrst choice in patients
with moderate/large varices depending on patient’s
preferences and local resources.
 If no bleeding occurs treatment should be
maintained for life (unless the liver disease improves
and signiﬁcant portal hypertension disappears).
The addition of isosorbide 5-mononitrate (ISMN)
signiﬁcantly increases HVPG response to beta-adren-
ergic blockers [121]. However, it is less clear whether
this translates into a greater clinical eﬃcacy in pri-
mary prophylaxis. An open trial comparing nadolol
vs nadolol + isosorbide mononitrate demonstrated a
signiﬁcant lower rate of ﬁrst bleeding in the
combination group, without survival advantage
[122,123]. However, a large subsequent double-blind,
placebo-controlled study failed to conﬁrm these
results [124].Endoscopic band ligation (EBL) is eﬀective in pre-
venting the ﬁrst variceal bleeding in patients with med-
ium to large varices [125]. So far 17 trials have
compared EBL with beta-blockers for the primary pre-
vention of variceal bleeding [126–142]. The meta-analy-
sis of these trials (both including or excluding the studies
published as abstract) shows an advantage of EBL over
beta-adrenergic blockers in terms of prevention of ﬁrst
bleeding, without diﬀerences in mortality [143,144].
These results, however, have several problems. Firstly,
most trials were underpowered or lacked any sample size
calculation (11 out of 17 included less than 100 patients
when the sample size to detect a decrease in the inci-
dence of variceal bleeding at 2 years from 20% under
beta-blockers to a 12% with EBL under a two-sided
hypothesis with alpha 0.05 and beta 0.20 would be of
658 patients). The largest trial to date included only
152 [128]. Additionally, four of the trials were prema-
turely stopped [128,133,134,141]. Fig. 2 shows a strati-
ﬁed meta-analysis of the available trials. Pooling the
results from the 4 published trials that included more
than 100 patients (with a total of 462 patients) shows
no signiﬁcant beneﬁt of EBL over beta-blockers. The
analysis of trials published as abstracts (520 patients)
shows no beneﬁt from EBL over beta-blockers with sig-
niﬁcant heterogeneity. Only in the subgroup of pub-
lished trials with less than 100 patients (334 patients)
there was a signiﬁcant beneﬁt from EBL. This illustrates
that available evidence to favour EBL over beta-block-
ers is very weak.
Another source of controversy is the higher incidence
of adverse events in patients treated with beta-blockers
than with EBL [144]. In this regard, it should be noted
that while most side eﬀects related to beta-blockers
(hypotension, tiredness, breathlessness, impotence,
insomnia) were easily managed by adjusting the dose
or discontinuing the drug, patients did not require hos-
pital admission and no fatalities were observed [143],
side eﬀects related to EBL are of much greater signiﬁ-
cance, since most are bleeding episodes directly related
to the procedure, that frequently required hospitaliza-
tion and blood transfusion and resulted in three deaths
[128,141]. Further, long-term safety and beneﬁts of pro-
phylactic EBL are still uncertain. On the contrary, long-
term safety and eﬃcacy of non-selective beta-adrenergic
blockers are well established [145,146].
Cost-eﬀectiveness of EBL vs beta-blockers for pri-
mary prophylaxis has been compared in three deci-
sion-analysis studies with conﬂicting conclusions,
probably due to diﬀerent assumptions on the incidence
of variceal bleeding, quality of life with each treatment
and other portal hypertensive complications
[116,118,147]. Another variable to consider is patient’s
and physician preferences. A recent study evaluated pre-
dicted preferences from patients and physicians with an
interactive computer task. Sixty-four percent of the
Fig. 2. Meta-analysis (random eﬀects model) of randomised controlled trials comparing endoscopic band ligation (EBL) with beta-adrenergic blockers in
the prevention of ﬁrst variceal bleeding. The studies have been pooled in three groups: published studies that included more than 100 patients, published
studies but with less than 100 patients, and abstracts.
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of shortness of breath and hypotension [148], although
the option of switching from beta-blockers to EBL in
case of side eﬀects was not considered in the algorithm.
The recommendation made at the 2005 Baveno con-
sensus conference is that non-selective beta-blockers
should be considered as ﬁrst-choice treatment to prevent
ﬁrst variceal bleeding in patients with high-risk varices,
while EBL should be oﬀered to patients with contraindi-
cations or intolerance to beta-blockers [70] (Text Box 1).
The recently published guidelines by the AASLD and
the ACG consider beta-blockers as ﬁrst choice in
patients with medium/large varices that have not bled
and are not at the highest risk of haemorrhage (Child
A patients and no red signs), but in high-risk patients
both EBL and beta-blockers are considered ﬁrst choice
[149].
The combination of pharmacology and endoscopic
therapy has been investigated with contrasting results.
In one study band ligation plus beta-adrenergic blockersoﬀered no beneﬁt in terms of prevention of ﬁrst bleeding
when compared to band ligation alone [150]. In a more
recent study combination therapy signiﬁcantly reduced
the occurrence of the ﬁrst episode of variceal bleeding
and improved bleeding-related survival in a group of cir-
rhotic patients with high-risk oesophageal varices in the
waiting list for liver transplantation [140]. Probably
more studies would be required, although these are unli-
kely to be performed due to the very large number of
patients that would be needed.
4.3. Unanswered issues
4.3.1. HVPG monitoring. Is it worth it? What is its
target?
Longitudinal studies have demonstrated that a
decrease in HVPG < 12 mm Hg essentially eliminates
the risk of bleeding and improves survival [6], while
reductions >20% from baseline [146,151] or even >10%
from baseline [152] signiﬁcantly decrease the risk of ﬁrst
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HVPG measurements should be used to monitor
response to drug treatment in clinical practice. Two sim-
ulation analyses have yielded conﬂicting results, one
suggesting that HVPG monitoring might be cost eﬀec-
tive in primary prophylaxis [153], and the other arriving
to the opposite conclusion [154]. Themain problem is that
the assumptions of these analyses (i.e. how to manage
non-responders to medical treatment) have never been
tested in randomised controlled trials. A recent study of
HVPG guided therapy suggested that the shift of non-
responders from beta-blockers to EBL does not improve
the outcome [155]. The issue will remain hypothetical
until HVPG guided therapy is proven better than empir-
ical approaches in randomised controlled trials.
4.3.2. Endoscopic treatment: how frequent, how to
monitor the treatment
There is no agreement on how frequently the varices
should be ligated in the initial course of eradication, the
interval varying from 1 to 4weeks [128,133]. A recent trial
evaluated the eﬀectiveness and complications of EBL
every two weeks vs every two months. This trial included
patients with andwithout previous bleeding, thoughmost
patients were treated for primary prophylaxis [156]. The
two-month interval scheme obtained a higher total erad-
ication rate and lower recurrence rate.Nopatient in either
group bled. Thus, although admittedly weak, current evi-
dence favours monthly intervals. This might not apply to
prophylaxis of recurrent bleeding (inwhich the risk of reb-
leeding ismaximal in the ﬁrst fewweeks)where a 1–2week
interval might be more appropriate. Once the varices are
eradicated, follow-up endoscopies should be performed
at 1–3 months and every 6 months thereafter, and varices
should be re-eradicated upon recurrence. This is in
marked contrast with prophylaxis with beta-blockers, in
which no follow-up endoscopies are needed.5. Prevention of recurrent bleeding from oesophageal
varices
Patients surviving a ﬁrst episode of variceal bleeding
have a risk of over 60%of experiencing recurrent haemor-
rhage within two years from the index episode. Because of
this, all patients surviving variceal bleeding should receive
active treatments for the prevention of rebleeding [70].
Available treatments for preventing variceal reblee-
ding include pharmacological therapy, endoscopic ther-
apy, TIPS and surgical shunting (Fig. 3).
Pharmacological therapy. Non-selective beta-blockers
are the ﬁrst-line pharmacological therapy for the preven-
tion of rebleeding [70]. Several meta-analyses have consis-
tently found a marked beneﬁt of beta-blockers showing a
reduction in rebleeding rate from 63% in controls to 42%
in treated patients [120]. Notably, beta-blockers alsoinduce a signiﬁcant decrease of overall mortality from
27% to 20% [120] and of mortality due to bleeding [157].
Beta-blockers have been compared with endoscopic
variceal sclerotherapy in the prevention of rebleeding.
No signiﬁcant diﬀerences were found either for reblee-
ding or for mortality but side eﬀects were signiﬁcantly
less frequent and severe with beta-blockers [120].
The combination of propranolol or nadolol plus 5-iso-
sorbide mononitrate (ISMN) enhances the reduction of
portal pressure induced by non-selective beta-blockers
[121]. There is only one published study comparing
ISMN associated with propranolol [158] vs propranolol
alone in the prevention of rebleeding. The study showed
a signiﬁcant beneﬁt of the pharmacological association.
The association of propranolol/nadolol and ISMN has
been compared with endoscopic sclerotherapy [159]
showing less rebleeding in the pharmacological treat-
ment arm, and with band ligation (EBL) in 4 studies
[160–163]. A meta-analysis of the 4 studies vs EBL have
shown no signiﬁcant diﬀerences between both treat-
ments in preventing rebleeding or in mortality. The asso-
ciation of beta-blockers and ISMN seems to be the best
pharmacological approach to prevent rebleeding [149].
Endoscopic treatment is a local treatment aimed at
eradicating the varices. Since it does not decrease on
portal pressure, varices may recur after endoscopic
treatment, and patients need to receive a life-long endo-
scopic follow-up to detect variceal recurrence.
Endoscopic injection sclerotherapy of oesophageal var-
ices signiﬁcantly reduces both the rebleeding and death
risk. It takes 4–6 endoscopic sessions to eradicate varices,
but recurrence of varices occurs in nearly 40% of patients
within one year from eradication. The most serious side
eﬀects of therapy are dysphagia, oesophageal stenosis
and bleeding from oesophageal ulcers, which may
account for asmuch as 14% of all the rebleeding episodes.
As commented above, sclerotherapy has no advantage
over drug therapy and causes more frequent and severe
side eﬀects, and has been abandoned since the advent of
EBL.
Endoscopic banding ligation (EBL) is clearly superior
to sclerotherapy [143], due to less frequent and severe
complications. Thus, EBL is at present the endoscopic
treatment of choice [70]. Variceal eradication is achieved
with a lower number of EBL sessions than with sclero-
therapy, but EBL is associated with higher rate of recur-
rence of varices [143].
Combined endoscopic treatment: Sclerotherapy has
been added (either simultaneously or after the reduction
of variceal size to small) to EBL and compared to EBL
alone. Meta-analysis of these studies does not show any
beneﬁt either for rebleeding or for mortality, and it also
shows a trend towards an increasing complication rate
with combination endoscopic therapy [164]. Therefore,
there is no rationale to combine both endoscopic
approaches.
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The combination of the best endoscopic treatment
(EBL) and the best pharmacological treatment (beta-
blockers + ISMN) may be the best choice in prevention
of rebleeding [70,165] (Text Box 2).
Text Box 2
Treatment of acute variceal bleeding: recommendations The best approach is the combined use of a vaso-
active drug, started from admission (or even dur-
ing transferral to hospital) and an endoscopic
procedure.
 Terlipressin, somatostatin, octreotide and vaso-
pressin + nitroglycerin (in this order of prefer-
ence) may be used. Drug therapy should be
maintained for 2–5 days.
 Endoscopic band ligation or injection sclerother-
apy (in this order of preference) are the endoscopic
treatments of choice in bleeding oesophageal vari-
ces. In bleeding gastric varices the best endoscopic
choice is obturation with tissue adesives.
 Endoscopy (and endoscopic treatment) should
be done within 12 h of admission.
 Prophylaxis of infection with broad spectrum
antibiotics should be given to all patients
TIPS should be used as a rescue procedure
when medical and endoscopic therapies fail.
Patients bleeding from gastric varices may
require an earlier decision for TIPS.The association of injection sclerotherapy and beta-
blockers has been compared with either sclerotherapy
or beta-blockers alone. The meta-analysis of the RCTs
comparing combination therapy with sclerotherapy
alone showed a signiﬁcant reduction of the rebleeding
risk with combination therapy, but no diﬀerences for
mortality [24]. Also when compared with beta-blockers
alone, combination therapy signiﬁcantly reduced the
rebleeding risk but without advantage for survival [120].
Two RCTs have shown that adding beta-blockers to
EBL reduces the risk of rebleeding andvariceal recurrence
[166,167], suggesting that if EBL is used, it should be used
in associationwith beta-blockers.A recentRCT, still pub-
lished as an abstract [168], has evaluated whether EBL
may improve the eﬃcacy of the combined administration
of nadolol + ISMN. In this study, adding band ligation to
nadolol plus ISMN was shown to be superior to nado-
lol + ISMN alone in preventing variceal rebleeding, but
there were no signiﬁcant diﬀerences in mortality.
5.1. Pending problems
5.1.1. HVPG guided therapy in the prevention of
rebleeding
Pharmacological (or spontaneous) reduction of
HVPG to <12 mm Hg or byP20% of the baseline value
(HVPG responders) decreases dramatically the risk of
rebleeding and signiﬁcantly reduces mortality [37]. The
rebleeding risk in the group of responders is as low as that
achieved using surgical shunts or TIPS [169]. As a conse-
quence, adding further treatment (i.e. band ligation) in
this group is unlike to enhance eﬃcacy, but may increase
severe side eﬀects. On the other hand, it is still uncertain
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response to pharmacological therapy (non-responders)
would beneﬁt from alternative treatments. In the study
by Bureau et al. [155], HVPG non-responders to beta-
blockers ± ISMN were shifted to receive endoscopic
band ligation without any beneﬁt. Preliminary data from
a Spanish multicenter RCT comparing nadolol + ISMN
vsNadolol + ISMN + EBL[168] foundno signiﬁcant dif-
ferences in rebleeding rates in HVPG non-responders
treatedwith drugs alone orwith drugs + EBL.These data
suggest that EBLmay not be the best alternative to reduce
rebleeding in non-responders. Probably more eﬀective
and aggressive therapies are needed to reduce the high
rebleeding risk of HVPG non-responders (46–65% in a
recent survey[169]). Indeed, Gonzalez et al. showed a
low rebleeding rate (19%) in HVPG non-responders trea-
ted with TIPS[170]. Unfortunately, the study did not
include a control group. Thus, until more data are avail-
able HVPG guided therapy should only be used in the set-
ting of clinical research.
5.1.2. The role of TIPS
TIPS has proven better than the combination of
ISMN and propranolol [171], and to endoscopic therapy
in the prevention of variceal rebleeding [172], with reb-
leeding rates of 9–23% for TIPS. However, as expected,
the high eﬀectiveness in preventing recurrent bleeding is
associated with an increased risk of encephalopathy,
without a survival beneﬁt. Because of this, TIPS is con-
sidered as salvage therapy for patients who bleed despite
adequate medical and endoscopic treatment. TIPS has
been compared with surgical shunts in two RCTs
(8 mm portocaval H-graft shunt in one, and distal sple-
norenal shunt (DSRS) in the second) [173,174]. The ﬁrst
study favoured surgical shunts, which showed a signiﬁ-
cantly lower rebleeding rate and a lower incidence of
the composite end-point of rebleeding, shunt thrombo-
sis, deaths, and need for transplant compared with
TIPS. There was no diﬀerence in mortality. The second
and larger trial [174] showed no signiﬁcant diﬀerences in
rebleeding rate (5.5% in the DSRS group, and 9% in the
TIPS group), incidence of hepatic encephalopathy, liver
transplantation or mortality. There was a signiﬁcantly
higher reintervention rate in the TIPS group (82%),
which used bare stents, than in the DSRS group
(11%). However, the obstruction and reintervention
rates can be markedly decreased with the use of polytet-
raﬂuoroethylene (PTFE)-covered stents [175]. Accord-
ing to these data, TIPS using PTFE-covered stents
represent the best rescue therapy for failures of medical
and endoscopic treatment.
5.2. Prevention of rebleeding from gastric varices
Gastric variceal bleeding is relatively uncommon and
there are few speciﬁc studies on its prevention. Type 1gastric varices (GOV 1) are an extension of oesophageal
varices along the lesser curvature of the stomach, and
their management is the same as for oesophageal
varices. Isolated gastric varices (IGV1) and fundal gas-
tro-oesophageal varices (GOV 2), are those who present
diﬀerential features. When IGV 1 are due to isolated
splenic vein thrombosis splenectomy is a curative treat-
ment. In acute bleeding from gastric varices, endoscopic
variceal obturation (EVO) with N-butyl-cyanoacrylate,
isobutyl-2-cyanoacrylate (bucrylate) or thrombin has
been shown to be more eﬀective than sclerotherapy or
EBL, and this extends to rebleeding [176–178].
Several papers demonstrated the eﬀectiveness of TIPS
in uncontrolled bleeding from gastric varices. In a
recently published RCT [179], TIPS proved more eﬀec-
tive than EVO in preventing rebleeding from gastric var-
ices with similar survival and frequency of
complications, despite the fact that TIPS stents were
not PTFE-covered, and rebleeding rate after TIPS was
much higher than previously reported, suggesting an
inaccurate TIPS follow-up. Recent AASLD practice
guidelines [149] advise the use of PTFE-covered TIPS
for the prevention of the rebleeding from gastric varices
in patients in whom bleeding recurs despite endoscopic
and pharmacological therapy, even after a single failure
has occurred. When patients do not present with acute
bleeding (or have survived for some weeks a bleeding
episode) non-selective beta-blockers are the usual treat-
ment for the prevention of rebleeding, although there is
limited information on its eﬃcacy.6. The acute bleeding episode
6.1. Natural history and prognosis
Ruptured oesophageal varices cause 70% of all upper
gastrointestinal bleeding episodes in patients with portal
hypertension [180]. Thus, in any cirrhotic patient with
acute upper gastrointestinal bleeding, a variceal origin
should be suspected. Diagnosis is established at emer-
gency endoscopy based on observing one of the follow-
ing: (a) active bleeding from a varix (observation of
blood spurting or oozing from the varix) (near 20% of
patients); (b) white nipple or clot adherent to a varix;
(c) presence of varices without other potential sources
of bleeding. Endoscopy should always be performed
with 12 h of admission (preferable within 6 h).
Initial control of bleeding. Because variceal bleeding is
frequently intermittent, it is diﬃcult to assess when the
bleeding stops and when a new haematemesis or melena
should be considered an episode of rebleeding. Several
consensus conferences have addressed this issue and
set deﬁnitions for events and timing of events related
to episodes of variceal bleeding [70]. Using these deﬁni-
tions, data from placebo-controlled clinical trials show
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50% of patients [120]. Currently available treatments
increase control of bleeding at 5 days to about 80% of
the patients [180].
Early rebleeding. The incidence of early rebleeding
ranges between 30% and 40% in the ﬁrst 6 weeks. The
risk peaks in the ﬁrst ﬁve days with 40% of all rebleeding
episodes occurring in this very early period, remain high
during the ﬁrst 2 weeks and decline then slowly in the
next 4 weeks. After 6 weeks the risk of further bleeding
becomes virtually equal to that before bleeding [181].
Early rebleeding is a strong predictor of death from var-
iceal bleeding. Prognostic indicators for early rebleeding
(assessed in most studies as a composite with failure to
control bleeding and ﬁve-day mortality) are summarized
in Table 3A.
Mortality. The general consensus is that any death
occurring within six weeks of hospital admission for var-
iceal bleeding should be considered as a bleeding-related
death [70]. This has greatly decreased in the last two
decades, from 42% in the late 70s [181] to the current
15–20% [180,182–184]. Immediate mortality from
uncontrolled bleeding is in the range of 4–8% [25,180].
Pre-hospital mortality from variceal bleeding might be
around 3% [185]. Nowadays only 40% of the deaths
are directly related to bleeding, while most are caused
by liver failure, infections and hepatorenal syndrome
[180]. Table 3B shows the most consistently reported
risk indicators for 6-week mortality.Table 3
Prognostic indicators, with their reported odds ratio/hazard ratio, for
ﬁve-day treatment failure (A) and 6-week mortality (B), in patients with
acute variceal bleeding
Variable OR/HR References
A: 5-day failure
HVPGP 20 mm Hg 5.4–11.4 [114,216,232]
Bacterial infection 4.6–9.7 [193,233,234]
Active bleeding at endoscopy 2.1–3.7 [180,193,235]
Portal vein thrombosis 3.1 [180,232]
Child-Pugh class 2.7 [180]
Child-Pugh score 1.2 [193]
Shock 4.9 [232]
AST levels (per IU increase) 1.003 [180]
B: 6-week mortality
At admission
Shock 5.8–9.9 [187,234]
Hepatocellular carcinoma 3.1–7.5 [180,236,237]
Hepatic encephalopathy 2.4–6.9 [180,234–236]
Active bleeding 5.4 [181]
Child-Pugh score 4.5 [233]
Prothrombin time, bilirrubin, albumin – [180,235,237]
Creatinine, urea – [235,237]
Late prognostic indicators
Renal failure 17.1–52.1 [187,236]
Bacterial infection 12.6 [234]
Early rebleeding 3.2–8.7 [235,236]
HVPG: hepatic venous pressure gradient.6.2. Treatment of acute variceal bleeding
Acute variceal bleeding should be managed in an
intensive care setting by a team of experienced medical
staﬀ, including well-trained nurses, clinical hepatolo-
gists, endoscopists, interventional radiologists, and sur-
geons [186]. Lack of these facilities demands
immediate referral. Decision-making shall follow the
guidelines set up in a written protocol developed to opti-
mize the resources of each center.
6.2.1. General management
The general management of the bleeding patient is
aimed at correcting hypovolemic shock (with judicious
volume replacement and transfusion) and at preventing
complications associated with gastrointestinal bleeding
(bacterial infections, hepatic decompensation, renal
failure), which are independent of the cause of the
haemorrhage and demand immediate management. Ini-
tial resuscitation should follow the classic Airway,
Breathing, Circulation scheme, and it is aimed at restor-
ing an appropriate delivery of oxygen to the tissues
(which depends on SaO2, cardiac output and haemo-
globin concentration). Airway should be immediately
secured, especially in encephalopatic patients, since
the patient is at risk of bronchial aspiration of gastric
content and blood. This risk is further exacerbated
by endoscopic procedures. Endothracheal intubation
is mandatory if there is any concern about the safety
of the airway.
Blood volume replacement should be initiated as
soon as possible with plasma expanders, aiming at main-
taining systolic blood pressure around 100 mm Hg.
Avoiding prolonged hypotension is particularly impor-
tant to prevent infection and renal failure, which are
associated with increased risk of rebleeding and death
[187]. Although it has been shown that volume expan-
sion may induce rebound increases in portal pressure
and rebleeding [188,189], the use of vasopressin ana-
logues or somatostatin blunt the increase in portal pres-
sure induced by volume expansion [190,191]. Thus, the
use of vasoactive drugs allows a less conservative blood
volume restitution policy. Blood transfusion should aim
at maintaining the hematocrit at 0.21–0.24 (Hb 7–8 g/l)
[70], except in patients with rapid ongoing bleeding or
with ischemic heart disease. The role of platelet transfu-
sion or fresh frozen plasma administration has not been
assessed appropriately. The use of recombinant acti-
vated factor VII (rVIIa, Novoseven), which corrects
prothrombin time in cirrhotics [192], has been assessed
in two randomised controlled trials. The ﬁrst trial
showed, in a post hoc analysis, that rFVIIa administra-
tion may signiﬁcantly improve the results of conven-
tional therapy in patients with moderate and advanced
liver failure (stages B and C of the Child-Pugh classiﬁca-
tion) without increasing the incidence of adverse events
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active bleeding at endoscopy and with a Child-Pugh
score P8 points. This trial failed to show a beneﬁt of
rVIIa in terms of decreasing the risk of 5-day failure
but improved 6-week mortality [74].
Infection is a strong prognostic indicator in acute
variceal bleeding [193]. The most frequent infections
are spontaneous bacterial peritonitis (50%), urinary
tract infections (25%) and pneumonia (25%). The use
of prophylactic antibiotics has been shown to reduce
both the risk of rebleeding [194] and mortality [195].
Therefore, antibiotics should be given to all patients
from admission. Quinolones are frequently used due to
its easy administration and low cost [196]. In high-risk
patients (hypovolemic shock, ascites, jaundice or malnu-
trition) i.v. ceftriaxone has recently been shown to be
superior to oral norﬂoxacin [197].
Variceal bleeding can trigger hepatic encephalopathy.
However, there are no data to support the prophylactic
use of lactulose or lactitol [70].
6.2.2. Speciﬁc therapy for control of bleeding
Initial therapy for acute variceal bleeding is based on
the combination of vasoactive drugs with endoscopic
therapy. Rescue therapies for failures include balloon
tamponade and portal–systemic shunts, either surgical
or TIPS.
6.2.2.1. Pharmacological therapy. The action of vasoac-
tive drugs is to reduce variceal pressure by decreasing
variceal blood ﬂow. The selection of the drug depends
on the local resources. Terlipressin should be the ﬁrst
choice if available, since it is the only drug that has been
shown to improve survival [120,198]. Somatostatin and
somatostatin analogues (octreotide or vapreotide) are
second choice [120,199]. If these drugs are not available
vasopressin plus transdermal nitroglycerin is an accept-
able option [120] (Table 2).
Terlipressin is a long-acting triglycyl lysine deriva-
tive of vasopressin. Clinical studies have consistently
shown less frequent and severe side eﬀects with terli-
pressin than with vasopressin (even if associated with
nitroglycerin).
Terlipressin may be initiated as early as variceal
bleeding is suspected at a dose of 2 mg/4 h for the ﬁrst
48 h, and it may be maintained for up to 5 days at a dose
of 1 mg/4 h to prevent rebleeding [200]. Compared with
placebo or non-active treatment terlipressin signiﬁcantly
improves the rate of control of bleeding and survival
[201]. This is the only treatment that has been shown
to improve prognosis of variceal bleeding in placebo-
controlled RCTs and meta-analysis [120,201]. Terlipres-
sin is as eﬀective as any other eﬀective therapy, including
endoscopic injection sclerotherapy (EIS), and is safer
than vasopressin+nitroglycerin and EIS [120,200,201].
The most common side eﬀect of this drug is abdominalpain. Serious side eﬀects such as peripheral or myocar-
dial ischemia occur in less than 3% of the patients
[200]. The overall eﬃcacy of terlipressin in controlling
acute variceal bleeding at 48 h is of 75–80% across trials
[201], and of 67% at 5-days [200]. Terlipressin is also use-
ful in hepatorenal syndrome [202]. Thus the use of terli-
pressin for variceal bleeding may prevent renal failure,
which is frequently precipitated by variceal bleeding
[187].
Somatostatin is empirically used as an initial bolus of
250 lg followed by a 250 lg/h infusion that is main-
tained until the achievement of a 24 h bleed-free period.
The bolus injection can be repeated up to three times in
the ﬁrst hour if bleeding is uncontrolled. Therapy may
be further maintained for up to 5 days to prevent early
rebleeding [203]. Major side eﬀects with somatostatin
are rare. Minor side eﬀects, such as nausea, vomiting
and hyperglycemia occur in up 30% of patients [203–
205]. Several randomised controlled trials showed that
somatostatin signiﬁcantly improves the rate of control
of bleeding compared with placebo or non-active treat-
ment, but mortality was not reduced [120,199]. Somato-
statin has been compared with terlipressin and no
diﬀerences were found for failure to control bleeding,
rebleeding, mortality or in the incidence of adverse
events in both treatment groups [120]. The use of higher
doses (500 lg/h) causes a greater fall in HVPG and
translates into increased clinical eﬃcacy and lower mor-
tality in the subset of patients with more diﬃcult bleed-
ings (those with active bleeding at emergency
endoscopy) [205].
Octreotide is a somatostatin analogue with longer
half-life. This, however, is not associated with longer
hemodynamic eﬀects [206]. The optimal doses are not
well determined. It is usually given as an initial bolus
of 50 lg, followed by an infusion of 25 or 50 lg/h
[199]. As with somatostatin, therapy can be maintained
for 5 days to prevent early rebleeding. The safety proﬁle
of octreotide is close to that of somatostatin. The eﬃ-
cacy of octreotide as a single therapy for variceal bleed-
ing is controversial. No beneﬁt from octreotide was
found in the only trial using octreotide or placebo as ini-
tial treatment [207], which may be due to rapid develop-
ment of tachyphylaxis [206]. However, RCT’s using
octreotide after of sclerotherapy have shown a signiﬁ-
cant beneﬁt in terms of reducing early rebleeding [208].
It has been speculated that this may be related to its abil-
ity to prevent post-prandial increase in portal pressure
[199]. Mortality, however, was not aﬀected [120,208].
These results suggest that octreotide may improve the
results of endoscopic therapy but has uncertain eﬀects
if used alone. When compared with other vasoactive
drugs, octreotide was better than vasopressin and equiv-
alent to terlipressin, again suggesting a clinical value
from the use of octreotide, although all these studies
were underpowered and none was double-blind [120].
Vasoactive drug therapy
+ prophylactic antibiotics
Endoscopy
Esophageal
variceal bleeding
Control of
bleeding?
Evaluate severity
Moderate Severe
Repeat endoscopic therapy
(if feasible)
Control of
bleeding?
balloon tamponade
if required
Continue vasoactive drugs
for 2-5 days.
Start long term treatment
TIPS / Surgery
Suspected Variceal 
Bleeding
YES
YES
NO
NO
Endoscopic Band Ligation
(Sclerotherapy if not feasible)
Resuscitation, prevention
of complications
Fig. 4. Algorithm of the management of acute bleeding from ruptured oesophageal varices.
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band ligation (EBL) have shown to be eﬀective in the
control of acute variceal bleeding. Two randomised tri-
als speciﬁcally compared band ligation and sclerother-
apy in acute variceal bleeding [209,210]. In one of
them all patients received also pharmacological therapy
(somatostatin) [210]. In eight additional trials these two
modalities were compared both in acute bleeding and in
the prevention of rebleeding. Meta-analysis shows that
EBL is better than sclerotherapy in the initial control
of bleeding, and is associated with less adverse events
and improved mortality. Additionally, sclerotherapy,
but not EBL, may increase portal pressure [211]. There-
fore EBL is the endoscopic therapy of choice in acute
variceal bleeding, though injection sclerotherapy is
acceptable if band ligation is not available or technically
diﬃcult. Endoscopic therapy can be performed at the
time of diagnostic endoscopy, early after admission,
provided that a skilled endoscopist is available. This is
important since there has been an increased frequency
of aspiration pneumonia since emergency endoscopic
therapy has become universal practice.
6.2.2.3. Current recommendations for initial treatment
(Fig. 4). The current recommendation is to start vasoac-
tive drug therapy early (ideally during the transferral orto arrival to hospital, even if active bleeding is only sus-
pected) and performing EBL (or injection sclerotherapy
if band ligation is technically diﬃcult) after initial resus-
citation when the patient is stable and bleeding has
ceased or slowed (Text Box 3). The rationale for this
comes from a number of RCT’s demonstrating that
early administration of a vasoactive drug facilitates
endoscopy and improves control of bleeding and 5-day
rebleeding [198,204,212,213]. Vice versa, the association
of endoscopic therapy also improves the eﬃcacy of
vasoactive treatment [204]. The optimal duration of
drug therapy is not well established. Current recommen-
dation is to maintain the drug for 2–5 days [70].
Text Box 3
Prevention of rebleeding: recommendations Patients with cirrhosis who survive a variceal
bleeding episode have a very high risk of reb-
leeding (about 60% at 1-yr).
 All patients surviving a bleeding episode should
receive speciﬁc therapy to prevent rebleeding.
 Non-selective beta-blockers ± ISMN, endoscopic
band ligation (EBL)orboth shouldbeused for preven-
tion of recurrent bleeding.Combination of beta-block-
ers ± ISMN and EBL may be the best treatment.
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for primary prophylaxis, EBL should be added to
drug treatment. Similarly, in patients previously
treated with EBL and with no contraindication to
beta-blockers, propranolol or nadolol should be
added to EBL.
 TIPS is very eﬀective in the prevention of recurrent
bleeding from oesophageal varices, and the eﬃcacy
is not signiﬁcantly diﬀerent from that of shunt sur-
gery (distal splenorenal shunt or 8 mm H-graft
shunt), especially since the introduction of PTFE-
covered stents. However TIPS does not improve
survival and therefore it should be only oﬀered to
patients who rebleed from oesophageal or gastric
varices despite optimal medical and/or endoscopic
treatment.
 It is possible that high-risk patients may beneﬁt
from an early decision for TIPS, but this should be
further evaluated.6.2.3. Rescue therapies: tamponade, surgery and TIPS
In 10–20% of patients variceal bleeding is unrespon-
sive to initial endoscopic and/or pharmacologic treat-
ment. If bleeding is mild and the patient is stable a
second endoscopic therapy might be attempted. If this
fails, or bleeding is severe, the patient should be oﬀered
a derivative treatment, before his clinical status deterio-
rates further. Balloon tamponade achieves hemostasis in
60–90% of variceal bleedings [24] but should only be
used in the case of a massive bleeding, for a short period
of time (less than 24 h) as a temporal ‘‘bridge” until def-
inite treatment is instituted. Bleeding recurs after deﬂa-
tion in over half of the cases and severe complications
are common. A recent report suggests that the use of
oesophageal covered stents might achieve hemostasis
in most patients with refractory bleeding [72], with the
advantage over tamponade of less severe complications
despite longer periods of treatment. Adequately
designed trials should conﬁrm these ﬁndings.
Both TIPS and surgical shunts are extremely eﬀective
in controlling variceal bleeding (control rate approaches
95%), but due to worsening of liver function and
encephalopathy mortality remains high [24,214]. TIPS
is ﬁrst choice, since most patients requiring rescue treat-
ment have advanced liver disease with unacceptable sur-
gical risk. Anyhow, rarely, if ever, a patient with a
Child-Pugh score over 13 will survive TIPS. This clearly
indicates that some patients do not beneﬁt from TIPS in
this setting, and sometimes it is diﬃcult to make a clin-
ical based decision. Prognostic scores [215] may provide
objective parameters to ease the decision of not oﬀering
invasive treatments in diﬃcult cases.
A recent randomised trial explored whether patients
with poor prognostic indicators might beneﬁt from amore aggressive therapeutic approach ab initio. Patients
with high risk (with HVPG > 20 mm Hg) were random-
ised to receive standard therapy or TIPS. Those who
underwent early TIPS had signiﬁcantly less treatment
failure and lower mortality than patients undergoing
standard therapy [216]. An ongoing multicenter study
will conﬁrm whether early TIPS (performed with cov-
ered stents) is superior to combination therapy in
high-risk patients (ISRCTN58150114).
6.3. Gastric varices
Gastric varices develop in approximately 20% of
patients with portal hypertension [217]. They are the
source of 5–10% of all upper digestive bleeding episodes
in patients with cirrhosis. The risk of gastric variceal
bleeding is lower than that of oesophageal variceal
bleeding, but gastric variceal bleeding, in particular that
from fundal varices, tends to be more severe, to require
more transfusions, and to have a higher mortality rate
[217]. Fundal varices account for 1–3% of variceal
bleeds.
The optimal treatment of gastric fundal varices has
not been determined, since there are few RCTs and most
data come from retrospective series. The initial treat-
ment is similar to that of oesophageal variceal bleeding,
including the administration of a vasoactive drug (either
terlipressin, somatostatin or a somatostatin analogue).
Balloon tamponade, with the Linton-Nachlas tube, has
been used with limited success [71,218], but may serve
as a bridge to derivative treatments in massive bleedings.
Some endoscopic therapies are promising, but quality
information is scarce, and most studies include both fun-
dal varices and gastro-oesophageal varices. Sclerother-
apy, variceal obturation with tissue adhesives (‘‘glue
injection”), thrombin, EBL and ligation with large
detachable snares have been reported [219]. In most
uncontrolled series cyanoacrylate has reported a high
rate of control of bleeding (about 90%) [220]. Two
recent randomised trials compared EBL with cyanoacry-
late injection. In one trial cyanoacrylate injection was
more eﬀective and safer than EBL in the control of acute
bleeding, and was associated with less rebleeding [176].
In another trial both treatments were equally eﬀective
controlling acute bleeding, but rebleeding was more fre-
quent in the EBL group [178]. In another study, cyano-
acrylate was better than sclerotherapy both in achieving
initial hemostasis and in achieving faster variceal oblit-
eration [177]. These trials suggest that cyanoacrylate
injection is the most eﬀective endoscopic therapy in
acute bleeding from gastric fundal varices. This tech-
nique however needs expertise, and is usually not feasi-
ble during active bleeding.
TIPS is very eﬀective in the treatment of bleeding gas-
tric varices, with more than 90% success rate for initial
hemostasis and very low rebleeding rate [221,222]. A
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glue injection in preventing rebleeding [223]. Derivative
and devascularization surgery are also eﬀective, but with
limited applicability in advanced cirrhosis. Another
approach is the retrograde intravascular obliteration of
spontaneous splenorenal shunts that are frequently pres-
ent in patients with large fundal varices [224]. To date,
however, this treatment has not been tested in RCTs.
The authors’ recommendation is to start treatment
with a vasoactive drug. If bleeding is not controlled
and if an expert endoscopist is available, variceal obtu-
ration might be attempted. In cases of massive bleeding
or after failure of previous therapies, TIPS (or surgical
shunt in Child A patients) is mandatory. A second
attempt at endoscopic therapy should never be allowed
in these patients.
6.4. Portal hypertensive gastropathy (PHG)
Portal hypertensive gastropathy is a macroscopic
ﬁnding of a characteristic mosaic like pattern of the gas-
tric mucosa (‘‘mild” PHG), red-point lesions, cherry red
spots, and/or black-brown spots (‘‘severe” PHG) [225].
These lesions, however, are not entirely speciﬁc, i.e.
can occur in the absence of portal hypertension. In
PHG there is marked dilatation of the vasculature of
the gastric mucosa and submucosa, together with an
increased blood ﬂow and tendency to decreased acid
secretion. PHG is unrelated to Helicobacter pylori infec-
tion. The overall prevalence of PHG in patients with cir-
rhosis strongly correlates with the severity of the disease
and ranges between 11% and 80% [225]. The incidence
of acute bleeding is low (less than 3% at 3 years) with
a mortality of 12.5%, while the incidence of chronic
bleeding is 10–15% at 3 years. In acute bleeding from
PHG beta-adrenergic blockers, somatostatin, octreo-
tide, vassopressin, terlipressin and estrogens have been
proposed based on their ability to decrease gastric perfu-
sion in this condition [226–229]. However, only one
uncontrolled study so far has evaluated one of these
drugs (somatostatin) in acute bleeding from PHG
[230]. Hemostasis was achieved in all patients. Non-
selective beta-blockers eﬀectively decrease chronic bleed-
ing from PHG [231].Acknowledgement
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